A J Barrett

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Conditioning regimens for allogeneic stem cell transplants
    A J Barrett
    Allogeneic Stem Cell Transplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    Curr Opin Hematol 7:339-42. 2000
  2. pmc Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol
    Margaret F Bevans
    National Institutes of Health Clinical Center, Bethesda, MD, USA
    Health Qual Life Outcomes 9:24. 2011
  3. ncbi request reprint Are UC blood transplants prone to developing leukemia?
    J Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 2012, USA
    Cytotherapy 9:611-2. 2007
  4. ncbi request reprint Emerging therapeutic strategies for myelodysplastic syndrome
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, NIH, Building 10, Room 7C103, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Hematol Rep 2:193-201. 2003
  5. ncbi request reprint Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
    B N Savani
    Stem Cell Transplantation Section, Hematology Branch, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 21:2145-52. 2007
  6. ncbi request reprint Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    N Engl J Med 343:750-8. 2000
  7. ncbi request reprint A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
    R Nakamura
    Stem Cell Allogeneic Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Bone Marrow Transplant 37:353-8. 2006
  8. pmc Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein
    A S M Yong
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 25:629-37. 2011
  9. ncbi request reprint Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft
    M E Horwitz
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 344:881-8. 2001
  10. ncbi request reprint In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation
    D E Epperson
    Bone Marrow Transplant Unit, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 114:57-62. 2001

Detail Information

Publications73

  1. ncbi request reprint Conditioning regimens for allogeneic stem cell transplants
    A J Barrett
    Allogeneic Stem Cell Transplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    Curr Opin Hematol 7:339-42. 2000
    ....
  2. pmc Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol
    Margaret F Bevans
    National Institutes of Health Clinical Center, Bethesda, MD, USA
    Health Qual Life Outcomes 9:24. 2011
    ....
  3. ncbi request reprint Are UC blood transplants prone to developing leukemia?
    J Barrett
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 2012, USA
    Cytotherapy 9:611-2. 2007
  4. ncbi request reprint Emerging therapeutic strategies for myelodysplastic syndrome
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, NIH, Building 10, Room 7C103, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Hematol Rep 2:193-201. 2003
    ..We describe recent developments of methods to manage marrow failure, suppress the MDS clone, and widen the applicability of curative treatment with allogeneic stem cell transplants...
  5. ncbi request reprint Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
    B N Savani
    Stem Cell Transplantation Section, Hematology Branch, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 21:2145-52. 2007
    ..7, P=0.028) and improved survival (HR 11.4, P=0.03). Results suggest that T cell-depleted SCT might be improved and the GVL effect enhanced by selecting donors with favorable KIR genotype, and by optimizing CD34 and CD3 doses...
  6. ncbi request reprint Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    N Engl J Med 343:750-8. 2000
    ....
  7. ncbi request reprint A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis
    R Nakamura
    Stem Cell Allogeneic Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Bone Marrow Transplant 37:353-8. 2006
    ..The GvMC effect can be observed after nonmyeloablative HCT with limited efficacy. Effective cytoreductive therapy prior to HCT may be required for long-term disease control and cure...
  8. pmc Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein
    A S M Yong
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 25:629-37. 2011
    ..A higher BMI-1 expression in CML CD34(+) progenitors was associated with native BMI-1 immune responses. These immune responses to PcG proteins may target leukemia stem cells and have relevance for disease control by GVL...
  9. ncbi request reprint Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft
    M E Horwitz
    Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 344:881-8. 2001
    ..We investigated the feasibility of stem-cell transplantation without ablation of the recipient's bone marrow...
  10. ncbi request reprint In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation
    D E Epperson
    Bone Marrow Transplant Unit, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 114:57-62. 2001
    ..These findings suggest that alloresponses involve multiple T-cell clones within a restricted TCR V beta repertoire that undergo different selection pressures in vitro and in vivo...
  11. ncbi request reprint Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back
    R Nakamura
    Stem Cell Transplantation Unit, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 115:95-104. 2001
    ..83 x 10(5) CD3(+) cells/kg. These results further define the impact of CD34 and CD3 cell dose on transplant outcome and show that careful dosing of stem cells and lymphocytes may permit the control and optimization of transplant outcome...
  12. ncbi request reprint Large granular lymphocyte leukaemia is characterized by a clonal T-cell receptor rearrangement in both memory and effector CD8(+) lymphocyte populations
    J J Melenhorst
    Bone Marrow Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 112:189-94. 2001
    ..These results suggest that LGL disease originates in a CD57(-) memory T-cell compartment that continually generates CD57(+) (effector cell) progeny...
  13. doi request reprint Regulatory T-cell depletion does not prevent emergence of new CD25+ FOXP3+ lymphocytes after antigen stimulation in culture
    J J Melenhorst
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1202, USA
    Cytotherapy 10:152-64. 2008
    ..The removal of human regulatory T (T(reg)) cells from a cellular product prior to the induction of a T-cell response has the potential to boost the total yield of antigen (Ag)-specific CD4(+) and CD8(+) T cells...
  14. ncbi request reprint Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs
    H Fujiwara
    Allogeneic Stem Cell Transplant Section, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA
    Bone Marrow Transplant 32:371-8. 2003
    ..These leukemia-restricted T-cells were CD8+ or CD4+ and CD25+ or CD57+. The results support the development of strategies to selectively deplete GVHD and conserve GVL reactivity in mismatched transplants...
  15. pmc Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy
    A S M Yong
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, M20892 1202, USA
    Leukemia 22:1721-7. 2008
    ....
  16. ncbi request reprint Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation
    C D Bolan
    Department of Transfusion Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
    Blood 98:1687-94. 2001
    ..The clinical manifestations of these events are affected by the degree and duration of residual host hematopoiesis...
  17. ncbi request reprint The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia
    E Sloand
    Stem Cell Allotransplantation Section, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Bone Marrow Transplant 32:897-901. 2003
    ..These results suggest that cytoreduction is required to optimize the curative effect of allogeneic stem cell transplantation for CML...
  18. pmc Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success
    Elaine M Sloand
    Hematology Branch, Division of Intramural Research, National Heart, Lung and Blood Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Hematol Oncol Clin North Am 24:331-41. 2010
    ..This article describes the laboratory evidence supporting a role for the immune system in the marrow failure of MDS and clinical trials using IST in these patients...
  19. ncbi request reprint Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation
    S R Solomon
    Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Bathesda, MD 20892, USA
    Bone Marrow Transplant 31:783-8. 2003
    ..Similarly, no significant differences were found in chronic GVHD, transplant-related mortality, or survival. These results define a role for CSA in preventing GVHD at low T-cell doses following PBSCT...
  20. ncbi request reprint Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity
    K Rezvani
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytotherapy 9:245-51. 2007
    ..However, little is known about the nature, origin and kinetics of the anti-leukemic T-cell responses involved...
  21. ncbi request reprint Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility
    C D Bolan
    National Institutes of Health, Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, Bethesda, MD 20892-1184, USA
    Br J Haematol 112:787-95. 2001
    ..Meticulous clinical monitoring and early, vigorous donor-compatible red cell transfusions should be practiced in all instances...
  22. ncbi request reprint High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial
    J F Tisdale
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Lancet 356:1554-9. 2000
    ....
  23. ncbi request reprint Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation
    B N Savani
    Stem Cell Allogeneic Transplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Building 10, Hatfield CRC, 10 Center Drive MSC 1202, Bethesda, MD 20892 1202, USA
    Bone Marrow Transplant 36:1009-15. 2005
    ..Four patients receiving nonconcurrent DLI+IM are also alive in MR. In conclusion, DLI appears to synergize with IM to induce rapid and durable MR...
  24. ncbi request reprint CD8+ T cells in large granular lymphocyte leukemia are not defective in activation- and replication-related apoptosis
    J J Melenhorst
    Bone Marrow Transplant Unit, Hematology Branch, NHLBI, National Institutes of Health, Building 10, Room 7C103, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Leuk Res 25:699-708. 2001
    ..Together, these data indicate that activation- and proliferation-related cell death mechanisms are functional in LGL cells...
  25. ncbi request reprint High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
    R Nakamura
    Stem Cell Allogeneic Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, MD 20892, USA
    Bone Marrow Transplant 30:235-42. 2002
    ..This strategy was associated with effective control of CMV antigenemia in the majority of patients and near-complete eradication of fatal CMV IP...
  26. ncbi request reprint Phenotype and function of a CD56+ peripheral blood monocyte
    G Sconocchia
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Leukemia 19:69-76. 2005
    ..These results define a minor monocyte population with distinct phenotypic and functional features...
  27. ncbi request reprint Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome
    M Stetler-Stevenson
    Laboratory of Pathology and the Biostatistics, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 98:979-87. 2001
    ..It is concluded that flow cytometric immunophenotyping may help establish the diagnosis of MDS, especially when morphology and cytogenetics are indeterminate. (Blood. 2001;98:979-987)..
  28. ncbi request reprint Selective depletion strategies in allogeneic stem cell transplantation
    S Mielke
    Stem Cell Allogeneic Transplantation Section, National Heart, Lung and Blood Institute NIH, Bldg 10 CRC Room 3 5288, 10 Center Drive, Bethesda, MD 20892, USA
    Cytotherapy 7:109-15. 2005
    ..Our review highlights the diversity of possible approaches and the need to develop different techniques for specific clinical applications...
  29. ncbi request reprint Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis
    R Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Br J Haematol 124:777-86. 2004
    ..0001). These data suggest that a co-ordinated approach using immunoregulatory monoclonal antibodies, pre-emptive antimicrobial therapy and judicious steroid withdrawal can dramatically improve outcome in steroid-refractory aGVHD...
  30. pmc Prolonged chronic graft-versus-host disease is a risk factor for thyroid failure in long-term survivors after matched sibling donor stem cell transplantation for hematologic malignancies
    Bipin N Savani
    Stem Cell Transplantation Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Biol Blood Marrow Transplant 15:377-81. 2009
    ....
  31. ncbi request reprint Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation
    S R Solomon
    Stem Cell Allotransplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD 20892 1652, USA
    Cytotherapy 4:395-406. 2002
    ....
  32. ncbi request reprint An APC for every occasion: induction and expansion of human Ag-specific CD4 and CD8 T cells using cellular and non-cellular APC
    M Grube
    Hematology Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD 20892, USA
    Cytotherapy 6:440-9. 2004
    ..In this review we outline the functional requirements of APC for the induction of T cells, classify the APC in common use and describe their laboratory and clinical applications...
  33. ncbi request reprint Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population
    K J Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 184:1093-7. 2001
    ..A chain of transmission within the outpatient clinic appeared to have occurred in 4 outpatients and to have extended to 2 hospitalized patients. Molecular epidemiology was useful in discerning routes of transmission in this outbreak...
  34. ncbi request reprint Pulmonary function following total body irradiation (with or without lung shielding) and allogeneic peripheral blood stem cell transplant
    B P Soule
    Radiation Biology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
    Bone Marrow Transplant 40:573-8. 2007
    ..TBI with or without lung dose reduction has a small but statistically significant effect on pulmonary function measured at 1 year but not 2 years post irradiation...
  35. ncbi request reprint Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation
    M F Bevans
    Department of Nursing, National Institutes of Health, Bethesda, MD 20892, USA
    Bone Marrow Transplant 38:101-9. 2006
    ..Two-year survivors report a return to baseline or better in HRQL by day 100, with the exception of physical health in MT patients...
  36. ncbi request reprint Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents
    A J Barrett
    Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda MD 20892 1202, USA
    Leukemia 20:1661-72. 2006
    ..This review examines the origins of RIC SCT, explores the degree to which the initial expectations and purpose of the approach have been realized, and outlines some ways forward for the field...
  37. pmc Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Clin Exp Immunol 148:189-98. 2007
    ..These promising early results point the way to optimizing the administration of peptide vaccines and suggest ways of combining vaccination with allogeneic stem cell transplantation to boost GVL effects...
  38. ncbi request reprint Flow cytometric quantitation and characterization of the T-lymphocyte memory response to CMV in healthy donors
    N Hensel
    Stem Cell Transplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cytotherapy 4:29-40. 2002
    ..Levels of circulating CMV Ag-specific lymphocytes determine CMV reactivation risk in immunocompromised individuals...
  39. ncbi request reprint Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
    Ramaprasad Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA
    Exp Hematol 34:796-801. 2006
    ..We investigated serum protein pattern analysis using surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry as a tool to diagnose GVHD...
  40. ncbi request reprint Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process
    D E Epperson
    Bone Marrow Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, National Institute of Health, 2000 Rockville Pike, Building 10, Rm. 7C 103, Bethesda, MD 20892, USA
    Leuk Res 25:1075-83. 2001
    ..These findings provide further evidence that T cell mediated immune processes are a feature of MDS...
  41. ncbi request reprint Cytotoxic lymphocytes for the clinic
    A J Barrett
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytotherapy 8:93-4. 2006
  42. ncbi request reprint Can we use monoclonal antibodies to help T cells fight tumors?
    A J Barrett
    National Heart, Lung and Blood Institute, Bethesda, Maryland 20892 1202, USA
    Cytotherapy 8:1-2. 2006
  43. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 13N240, 10 Center Drive, MSC 1928, Bethesda, MD 20892 1928, USA
    Hematol Oncol Clin North Am 17:1243-60. 2003
    ..Efforts to improve outcome for older patients and for patients with alternative donors have led to decreased treatment-associated complications with associated better long-term DFS...
  44. ncbi request reprint Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease
    M R Robinson
    National Eye Institute NIH, 10 10S229, 110 Center Drive, MSC 1863, Bethesda, MD 20892 1863, USA
    Bone Marrow Transplant 33:1031-5. 2004
    ..Additional studies are required to determine the long-term safety and efficacy of topical corticosteroids for cicatricial conjunctivitis associated with ocular GVHD in the context of a randomized, prospective clinical trial...
  45. doi request reprint Does chemotherapy modify the immune surveillance of hematological malignancies?
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Leukemia 23:53-8. 2009
    ....
  46. ncbi request reprint Transcription patterning of uncoupled proliferation and differentiation in myelodysplastic bone marrow with erythroid-focused arrays
    Y T Lee
    Laboratory of Chemical Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Blood 98:1914-21. 2001
    ..A distinct pattern of significantly increased proliferation-associated and reduced differentiation-associated gene activity was established for MDS...
  47. ncbi request reprint Manipulating regulatory T cells
    A J Barrett
    Stem Cell Allotrransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    Cytotherapy 9:109-10. 2007
  48. ncbi request reprint Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia
    M K Magnusson
    Hematology Branch, National Heart, Lung, and Blood Institute, and Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 98:2518-25. 2001
    ..Early endosomal transport is critical in regulation of various growth factor receptors, through ligand-induced clathrin-mediated endocytosis, and thus this new fusion protein links together 2 important pathways of growth regulation...
  49. ncbi request reprint Immune-globulin prophylaxis of respiratory syncytial virus infection in patients undergoing stem-cell transplantation
    K Cortez
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1882, USA
    J Infect Dis 186:834-8. 2002
    ..The subset of patients with the lowest titers appear to receive the greatest benefit from administration of RSVIG...
  50. pmc Immunotherapy prospects for acute myeloid leukaemia
    A J Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1202, USA
    Clin Exp Immunol 161:223-32. 2010
    ..Here we describe what is known about the immunological features of AML at presentation and in remission, the current status of immunotherapy and strategies combining treatment approaches with a view to achieving leukaemia cure...
  51. ncbi request reprint Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia
    E Clave
    Bone Marrow Transplantation Unit, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1652, USA
    J Immunother 22:1-6. 1999
    ..These data support the possibility that T-cell responses to allelic differences of proteinase 3 could be used as a basis for designing leukemia-specific adoptive T-cell therapy in acute and chronic myeloid leukemias...
  52. ncbi request reprint Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma
    Susann Szmania
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    J Immunother 30:847-54. 2007
    ..MAGE-A3 immunization may be a useful adjunct to high dose melphalan-based peripheral blood stem cell transplant, providing a new therapeutic option for high-risk MM...
  53. ncbi request reprint Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation
    Pamela Stratton
    Reproductive Biology and Medicine Branch, National Institute of Child Health and Human Development, NIH, Bethesda, Maryland 20892 1109, USA
    Obstet Gynecol 110:1041-9. 2007
    ..To describe the diagnosis and management of female genital chronic graft-versus-host (GVH) disease, a complication of hematopoietic stem cell transplantation...
  54. ncbi request reprint Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Opin Immunol 18:592-8. 2006
    ..Many of these approaches appear feasible in clinical transplantation and have yielded promising initial results, but proof that the goal of controlled selective immune reconstitution can be achieved is still awaited...
  55. doi request reprint Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
    Elaine M Sloand
    National Heart, Lung and Blood Institute, Division of Intramural Research, Hematology Branch, Bethesda, MD 20892, USA
    J Clin Oncol 26:2505-11. 2008
    ..We evaluated patients with MDS treated with IST at our institution to determine their clinical course compared with a comparable supportive care only group...
  56. pmc CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins
    Elaine M Sloand
    National Heart Lung and Blood Institute, Bethesda, MD 20892, USA
    Blood 109:2399-405. 2007
    ..Knock-down of survivin by siRNA resulted in preferential loss of trisomy 8 cells. These results suggest that trisomy 8 cells undergo incomplete apoptosis and are nonetheless capable of colony formation and growth...
  57. ncbi request reprint Determining which patients with myelodysplastic syndrome will respond to immunosuppressive treatment
    John Barrett
    Haematologica 91:583-4. 2006
  58. ncbi request reprint Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy
    Richard Childs
    Stem Cell Transplant Unit, Hematology Branch, National Heart, Lung and Blood Insitute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 39:63-71. 2002
    ..Here we review the historical background, development, and preliminary clinical results of allogeneic stem cell transplantation as immunotherapy for solid tumors...
  59. ncbi request reprint Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens
    Hoon Kook
    Hematology Branch of the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 99:3668-75. 2002
    ..Our data indicate that multiple specific clones mediate the immune process in AA...
  60. ncbi request reprint Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene
    Magnus K Magnusson
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 100:1088-91. 2002
    ..These results suggest that STI571 may be an effective targeted therapy in patients with CMML related to PDGFbetaR fusion oncogenes...
  61. ncbi request reprint Allogeneic marrow transplantation--dinosaur or bird?
    John Barrett
    Cytotherapy 4:201-2. 2002
  62. ncbi request reprint New directions in allogeneic stem cell transplantation
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 39:1-2. 2002
  63. ncbi request reprint Nonmyeloablative allogeneic immunotherapy for solid tumors
    Richard W Childs
    Allogeneic Hematopoietic Cell Transplant Unit, Hematology Branch, National Heart, Lung, and Blood Institutes, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 55:459-75. 2004
    ..The improved safety and preliminary success of this transplant approach have justified applying allogeneic immunotherapy to patients with treatment-refractory solid tumors...
  64. ncbi request reprint Allogeneic stem cell transplantation for chronic myeloid leukemia
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 40:59-71. 2003
    ..This review describes the mechanism of cure of CML by SCT, current results of transplantation, factors determining outcome, management of relapsed or persistent disease, and recent treatment advances...
  65. ncbi request reprint Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers
    Ram Srinivasan
    National Institutes of Health, National Heart, Lung, and Blood INstitue, Bethesda, MD 20892, USA
    Semin Oncol 31:47-55. 2004
    ..The historical basis, development, and preliminary clinical results of allogeneic stem cell transplantation as a form of immunotherapy for treatment refractory solid tumors are reviewed...
  66. ncbi request reprint Neutrophil granule proteins as targets of leukemia-specific immune responses
    John Barrett
    Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Curr Opin Hematol 13:15-20. 2006
    ..Frequencies are higher in patients with myeloid leukemias, and highest in patients with chronic myeloid leukemia entering molecular remission after allogeneic stem cell transplantation...
  67. ncbi request reprint Are stem cells and T cells best transplanted separately?
    John Barrett
    Stem Cell Allotransplantation Section, Hematology Branch National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cytotherapy 6:529-32. 2004
  68. ncbi request reprint Optimizing engraftment--source and dose of stem cells
    Norbert Schmitz
    Stem Cell Transplant Unit, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Semin Hematol 39:3-14. 2002
    ..These findings are of clinical importance-an understanding of the impact of stem cell source and dose is essential to obtain optimum conditions for a successful outcome after transplant...
  69. ncbi request reprint Adoptive T-cell therapy for CMV
    John Barrett
    Cytotherapy 4:1. 2002
  70. pmc Modification of the ionizing radiation response in living cells by an scFv against the DNA-dependent protein kinase
    Shuyi Li
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Nucleic Acids Res 31:5848-57. 2003
    ..The ability to modify the radiation response in situ in living cells provides a link between biochemical, genetic and cytologic approaches to the study of double-strand break repair intermediates...
  71. ncbi request reprint The ultrasound screen for penetrating truncal trauma
    Faran Bokhari
    Department of Trauma, Stroger Hospital of Cook County, Chicago, Illinois 60612, USA
    Am Surg 70:316-21. 2004
    ....
  72. ncbi request reprint The graft-versus-tumor effect and escape of malignancy from immune regulation
    Vera Malkovska
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Cancer Chemother Biol Response Modif 20:273-89. 2002
  73. ncbi request reprint Design, synthesis, and evaluation of radiolabeled integrin alpha v beta 3 receptor antagonists for tumor imaging and radiotherapy
    Thomas D Harris
    Discovery Research, Bristol Myers Squibb Medical Imaging, North Billerica, MA 01862, USA
    Cancer Biother Radiopharm 18:627-41. 2003
    ..Tumors are visible as early as 0.5 hours PI. Radiotherapy studies in the c-neu Oncomouse model demonstrated a slowing of tumor growth at a dose of 15 mCi/m(2), and a regression of tumors at a dose of 90 mCi/m(2)...